Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

By X. Paoletti, K. Oba, T. Burzykowski, S. Michiels, Y. Ohashi, Jean-Pierre Pignon, P. Rougier, J. Sakamoto, D. Sargent, M. Sasako and 2 more. Journal of the American Medical Association (JAMA), 2010

796 citations recorded by the source corpus.

Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/5dc7cbd7bdc50dad0c241424e0996aa3e5ca0d4e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Cervantes
2. E. Smyth
3. D. Arnold
4. B. Nordlinger
5. C. Schuhmacher
6. M. Verheij
7. E. Van Cutsem
8. W. Allum

Citations in the corpus

• Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. (2010, background): “001) benefit for patients treated with fluorouracil-based adjuvant chemotherapy versussurgeryalone.(5) The 503-patient Medical Research Council Adjuvant Gastric Infusional Chemotherapy JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 28 NUMBER 35 DECEMBER 10 2010”
• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “001] in all subgroups tested [I, A] [53].”